Metagenomi, Inc. (NASDAQ:MGX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Metagenomi, Inc. (NASDAQ:MGX) have received a consensus rating of “Moderate Buy” from the five research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $9.00.

Several research analysts have recently weighed in on the company. Weiss Ratings downgraded Metagenomi from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday. Wells Fargo & Company reduced their target price on Metagenomi from $12.00 to $9.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Finally, Wall Street Zen raised Metagenomi from a “strong sell” rating to a “sell” rating in a research note on Monday, June 15th.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Renaissance Technologies LLC raised its stake in shares of Metagenomi by 25.4% during the 1st quarter. Renaissance Technologies LLC now owns 787,900 shares of the company’s stock worth $1,056,000 after buying an additional 159,500 shares during the period. XTX Topco Ltd raised its stake in shares of Metagenomi by 353.4% during the 4th quarter. XTX Topco Ltd now owns 68,994 shares of the company’s stock worth $112,000 after buying an additional 53,778 shares during the period. Quadrature Capital Ltd acquired a new position in shares of Metagenomi during the 4th quarter worth approximately $55,000. Bridgeway Capital Management LLC increased its position in shares of Metagenomi by 102.1% during the fourth quarter. Bridgeway Capital Management LLC now owns 395,800 shares of the company’s stock worth $641,000 after purchasing an additional 200,000 shares in the last quarter. Finally, Panagora Asset Management Inc. purchased a new stake in shares of Metagenomi during the fourth quarter worth approximately $53,000.

Metagenomi Trading Up 5.0%

Shares of NASDAQ:MGX opened at $1.25 on Friday. Metagenomi has a 12-month low of $1.13 and a 12-month high of $3.95. The company has a market capitalization of $47.06 million, a PE ratio of -0.54 and a beta of 0.64. The business has a 50 day moving average of $1.33 and a two-hundred day moving average of $1.48.

Metagenomi (NASDAQ:MGX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Metagenomi had a negative net margin of 384.61% and a negative return on equity of 51.23%. The company had revenue of $1.25 million during the quarter, compared to analyst estimates of $5.90 million. Equities research analysts predict that Metagenomi will post -2.13 earnings per share for the current fiscal year.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.